Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11965 Views
-
Last post by NHE
-
- 0 Replies
- 1172 Views
-
Last post by NHE
-
- 0 Replies
- 1943 Views
-
Last post by frodo
-
- 0 Replies
- 1245 Views
-
Last post by frodo
-
- 0 Replies
- 2109 Views
-
Last post by NHE
-
- 0 Replies
- 1698 Views
-
Last post by frodo
-
- 0 Replies
- 1311 Views
-
Last post by NHE
-
- 1 Replies
- 1792 Views
-
Last post by frodo
-
- 0 Replies
- 2522 Views
-
Last post by NHE